跳至主要内容
临床试验/NCT05298072
NCT05298072Unknown不适用

Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

University Hospital, Essen0 个研究点目标入组 180 人开始时间: 2022年4月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
180
主要终点
Cardiotoxicity during observational period

研究概览

简要总结

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • initial diagnosis of breast cancer
  • planned Anthracycline-based therapy
  • first-line chemotherapy
  • first visit before initiation of chemotherapy

排除标准

  • previous chemotherapy
  • medical history of cardiac disease
  • inflammation-modulating medication
  • medication with RAS inhibitors
  • pregnancy
  • autoimmune disease
  • drug addictions
  • unwilling or unable to provide informed consent

结局指标

主要结局

Cardiotoxicity during observational period

时间窗: continuous evaluation during observational period of 12 months

Defined according to IC-OS 2021 Consensus Criteria

次要结局

未报告次要终点

研究者

发起方
University Hospital, Essen
申办方类型
Other
责任方
Sponsor

相似试验